TP53 and cancer: After simvastatin treatment, a significant decrease in immunofluorescence staining of lipid rafts (CTXB) was detected in the mutant p53 plasmid transfected cells, and CTXB staining remained at high levels in vector or wild type p53-overexpressed cancer cells (Fig. 3D).